Strike Pharma

Next-generation precision medicine

Strike Pharma has developed a technology platform that enables the selective delivery of drugs, enclosed in nanoparticles, to specific cells in the body. With this innovation, immune cells can be reprogrammed inside the body (in vivo), which would offer significant advantages in treating autoimmune diseases and cancer.

This approach supports the development of next-generation CAR-T therapies  – an advanced form of immunotherapy where a patient’s T cells (a type of immune cells) are reprogrammed to recognize and eliminate harmful cells.

Currently, Strike Pharma is developing a drug candidate that reprograms T cells to attack B cells, aiming to improve treatments for certain autoimmune diseases.

Per Norlén brings extensive experience to the company, in leading innovative biotech companies. He has previously served as CEO of Alligator Bioscience, Targinta, Evaxion Biotech, and WntResearch.

Did you know?

© 2023 Copyright SmiLe Incubator